

Anti-DLL4 Antibody (Enoticumab)

Introduction

Enoticumab (REGN421, SAR153192) is an IgG1κ antibody targeting human DLL4. DLL4 is a ligand of the Notch signaling pathway that regulates fatty acid uptake through non-transcriptional regulation of macropinocytosis-dependent long-chain fatty acid uptake. Enoticumab has specific in vivo activity in an ovarian xenograft model. EGN421 (2.5mg/kg, once a week) resulted in 86% and 83% tumor growth inhibition in subcutaneous TOV-112D or intraperitoneal A2780 human tumor xenograft models in mice, respectively.

Product parameters

Alternative Names	SAR153192, REGN421
Target Accession	Q9NR61
Target	DLL4
CAS number	1192578-27-0
Molecular Weight	146.48 kDa
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	Immobilized human DLL4 His at 2 ug/mL can bind Anti-DLL4 Antibody (Enoticumab), EC50=0.003918 ug/mL.
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 μM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

■ Note

1. This product is for scientific research use only.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

